Daraxonrasib: Shifting the Paradigm in Metastatic Pancreatic Cancer

Creator: Rayan Salih
Published: 2026-06-02T23:14:51+00:00
Keywords: ancer, ASCO

For decades, clinicians treating metastatic pancreatic ductal adenocarcinoma (mPDAC) have operated under a somber reality.

Written and medically reviewed byRayan SalihContributing writer · PharmD, RPh

June 2, 2026 · 8 min read

For decades, clinicians treating metastatic pancreatic ductal adenocarcinoma (mPDAC) have operated under a somber reality. Pancreatic cancer remains one of the most lethal malignancies globally, characterized by aggressive biology, late-stage presentation, and a historical lack of effective targeted options. In the second-line setting, following progression on standard first-line combinations, the therapeutic options shrink dramatically to conventional cytotoxic chemotherapy regimens. These non-targeted treatments offer marginal utility, yielding median progression-free survival (PFS) of just 3 to 4 months and a median overall survival (OS) of 6 to 7 months, all while inflicting profound toxicities on an already fragile patient population.

However, data presented at the 2026 American Society of Clinical Oncology (ASCO) Plenary Session and concurrently published in The New England Journal of Medicine have fundamentally redefined expectations for this disease. The landmark Phase 3 RASolute 302 trial evaluating daraxonrasib (RMC-6236), an oral, potent, RAS(ON) multiselective tri-complex inhibitor, demonstrated unprecedented survival and quality-of-life benefits over standard chemotherapy. For oncologists, gastroenterologists, and advanced practice providers, this represents a practice-shifting evolution.

Why It Matters

An Unprecedented Efficacy Breakthrough

The holy grail of pancreatic cancer research has long been the direct therapeutic targeting of RAS, an oncogenic driver present in the vast majority of tumors but historically deemed “undruggable” due to its smooth protein topology. While first-generation inhibitors successfully targeted the inactive ‘off’ form of specific mutations (such as KRAS G12C), they left the active ‘on’ state untouched, limiting their utility in mPDAC, where other variants dominate.

Daraxonrasib circumvents this historical barrier by utilizing a highly innovative mechanism of action: it binds intracellularly to cyclophilin A to form a binary complex that directly engages the active, GTP-bound state of RAS—known as RAS(ON)—thereby successfully shutting down aberrant downstream mitogen-activated protein kinase (MAPK) signaling.

The therapeutic magnitude of this sustained inhibition, validated in the global, randomized Phase 3 RASolute 302 trial, is nothing short of historic. The trial randomized 500 pretreated mPDAC patients to receive either once-daily oral daraxonrasib (300 mg) or the investigator’s choice of standard-of-care cytotoxic chemotherapies (gemcitabine plus nab-paclitaxel, modified FOLFIRINOX, FOLFOX, or liposomal irinotecan plus fluorouracil and leucovorin). The outcomes shattered historical benchmarks:

A 60% Reduction in the Risk of Death: In both the primary RAS G12 subpopulation and the overall intention-to-treat (ITT) population, daraxonrasib achieved a hazard ratio (HR) for death of 0.40 (P<0.001) compared to standard chemotherapy.
Doubled Median Overall Survival: Patients treated with daraxonrasib achieved a median overall survival of 13.2 months, compared to 6.6 months in the chemotherapy arm for the RAS G12 cohort, and 6.7 months for the overall population. Clinically, achieving a median OS exceeding one year in a second-line mPDAC population is a feat never before recorded in a Phase 3 clinical trial.
Doubled Progression-Free Survival: Median PFS was nearly doubled, reaching 7.3 months with daraxonrasib versus 3.5 months with chemotherapy in the RAS G12 group (HR 0.45), and 7.2 months versus 3.6 months in the overall group (HR 0.49; P<0.001 for both).
Tripled Objective Response Rates (ORR): In an environment where tumors rarely shrink during second-line therapy, daraxonrasib produced an objective response rate of 33.2% in the RAS G12 population (compared to 11.8% with chemotherapy) and 31.6% in the overall population (compared to 11.2% with chemotherapy).

For healthcare providers, these numbers matter because they translate to tangible, extended timelines for patients who previously had mere months to live. The 12-month overall survival rate stood at 53.3% for the daraxonrasib arm compared to a dismal 18.7% for those on chemotherapy.

Who It Affects

Broad-Spectrum Patient Populations

A common limitation of modern targeted oncology is the narrowing of patient eligibility to micro-subgroups (e.g., matching a drug to a mutation found in less than 1–2% of patients). Daraxonrasib is distinct because it is a multiselective pan-RAS inhibitor, meaning it affects the vast majority of patients walking through your clinic doors.

Oncogenic mutations in the RAS family drive more than 90% of all pancreatic ductal adenocarcinomas, with standard substitutions heavily concentrated at KRAS codon 12. Daraxonrasib is selectively engineered to inhibit both wild-type and mutant RAS across KRAS, NRAS, and HRAS, safely capturing variants at glycine 12 (G12), glycine 13 (G13), and glutamine 61 (Q61).

The Patient Profile

The RASolute 302 trial systematically included a broad clinical spectrum of patients, confirming that daraxonrasib’s benefits are widely reproducible:

The RAS G12 Population: Comprising 91.8% of the trial cohort, this group reflects the standard clinical distribution of mPDAC, capturing variants like KRAS G12D and G12V. Efficacy was profoundly robust here, as noted by the 13.2-month median OS.
Non-G12 RAS Mutations and Wild-Type RAS: Approximately 8.2% of enrolled patients possessed less common mutations (G13 or Q61) or had no identified RAS mutation. Strikingly, even patients without a classic RAS mutation demonstrated a clear trend toward benefit (OS HR of 0.37). This is because tumors lacking clear upstream mutations can remain entirely dependent on wild-type RAS signaling pathways to drive tumor growth.
Advanced Clinical Signatures: The trial enrolled heavily compromised individuals—70% of whom presented with liver metastases, and nearly half of whom possessed an ECOG performance status of 1. Subgroup analyses revealed that the survival advantage remained remarkably consistent regardless of age, geographical region, or prior first-line chemotherapy exposure (whether a patient progressed on FOLFIRINOX or gemcitabine/nab-paclitaxel).

Ultimately, this drug affects almost your entire advanced pancreatic cancer panel, removing the clinical frustration of checking molecular pathology only to find a patient lacks a rare, targetable alteration.

What Changes

Redefining Clinical Practice and Management

The introduction of daraxonrasib requires immediate adaptations in how multi-disciplinary oncology teams navigate diagnostics, treatment sequencing, toxicity management, and patient quality-of-life assessments.

Shifting to an Oral, Non-Cytotoxic Standard of Care

The most immediate logistical change is the transition from burdensome, multi-agent intravenous cytotoxic infusions to a once-daily oral regimen (300 mg) administered in the outpatient setting. Treatment can be sustained continuously until disease progression or unacceptable toxicity.

Proactive Molecular Profiling

Because daraxonrasib targets the RAS pathway broadly, documentation of a patient’s RAS mutational status via next-generation sequencing (NGS) or liquid biopsies must occur early in the disease course. Though a positive mutation is not a strict barrier given wild-type efficacy, establishing the genomic landscape early ensures accurate tracking and characterization as targeted therapy options enter the mainstream.

A More Manageable, Less Toxic Tolerability Profile

For clinical nursing and oncology teams, the side-effect management paradigm will look completely different from conventional chemotherapy. Cytotoxic regimens are notorious for high-grade myelosuppression, severe fatigue, febrile neutropenia, and cumulative peripheral neuropathy. Daraxonrasib trades these systemic toxicities for a highly predictable, primarily low-grade, on-target dermatologic and gastrointestinal profile.

A side-by-side safety analysis highlights this clinical upgrade:

Fewer Severe Events: Grade 3 or higher treatment-related adverse events (TRAEs) were notably lower in the daraxonrasib group compared to chemotherapy (43.6% vs. 57.5%). Serious TRAEs were also significantly reduced (10.8% vs. 18.7%).
Dramatically Lower Discontinuation Rates: Toxicities led to treatment discontinuation in only 1.2% of patients on daraxonrasib, compared to 11.2% of patients on chemotherapy (where peripheral neuropathy was the leading cause of treatment cessation).
Primary Toxicities to Monitor: The most common TRAEs associated with daraxonrasib are rash (85.5%), diarrhea (58.1%), and stomatitis (53.1%). Grade 3 rash occurred in 13.7% of patients, and Grade 3 stomatitis occurred in 12.0%. Crucially, there were zero reported Grade 4 events for these primary side effects, and they are readily manageable through routine supportive care, standard dermatologic interventions, and temporary dose modifications. Providers must remain vigilant for rare but severe events, as one case of fatal treatment-related pneumonitis (0.4%) was reported.
Avoidance of Hematologic Crises: While chemotherapy patients frequently required dose reductions or hospitalizations due to neutropenia (38.3% any grade, 27.6% Grade ≥ 3) and anemia (39.7% any grade), daraxonrasib demonstrated negligible hematologic disruption, resulting in a 0% rate of hematologic or infectious hospitalizations (compared to 4.2% and 3.3%, respectively, in the chemotherapy arm).

Preserving Patient-Reported Quality of Life (QOL)

Survival extensions mean little if a patient spends those extra months in severe pain or is incapacitated by treatment. Daraxonrasib fundamentally changes the patient experience by actively delaying clinical deterioration.

Using validated quality-of-life metrics (EORTC QLQ-PAN26 and QLQ-C30), the RASolute 302 trial measured the time to deterioration for global health status and pancreatic cancer-related pain. The results revealed a profound benefit:

The median time to deterioration for cancer-related pain was delayed to 9.0 months with daraxonrasib, compared to just 3.7 months with chemotherapy.
The median time to deterioration for global health status-quality of life was more than doubled to 5.6 months with daraxonrasib versus 2.4 months with chemotherapy.

By effectively shrinking or stabilizing tumors without bringing about devastating systemic toxicity, daraxonrasib protects performance status, controls cancer symptoms, and preserves a meaningful quality of life.

Preparing Your Practice for the Future

The Phase 3 RASolute 302 trial marks a watershed moment in gastrointestinal oncology. Oral daraxonrasib has effectively redrawn the survival curve for previously treated metastatic pancreatic cancer, cutting the risk of death by more than half, doubling survival times, and improving tolerability and patient quality of life.

With the manufacturer actively advancing global regulatory filings—supported by the FDA’s Breakthrough Therapy Designation and Orphan Drug Designation—daraxonrasib is poised to rapidly become the undisputed standard of care in the second-line setting. Furthermore, healthcare providers should note that Revolution Medicines has an authorized Expanded Access Program (EAP) in place, providing a pathway for eligible patients to access this therapy prior to official commercial availability.

As look-ahead trials concurrently evaluate daraxonrasib in earlier neoadjuvant, adjuvant, and first-line combination settings, the era of pan-RAS targeted therapy has officially arrived. Healthcare providers must align their clinical pathways now—integrating early molecular profiling and setting up specialized oral-adherence and dermatologic support teams—to ensure patients can seamlessly benefit from this historic therapeutic leap.